US 12383522
Baclofen formulations and methods of minimizing patient exposure to metabolite variations
granted A61KA61K31/197
Quick answer
US patent 12383522 (Baclofen formulations and methods of minimizing patient exposure to metabolite variations) held by AMNEAL PHARMACEUTICALS LLC expires Mon Aug 07 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- AMNEAL PHARMACEUTICALS LLC
- Grant date
- Tue Aug 12 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Aug 07 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 16
- CPC classes
- A61K, A61K31/197